News and Trends 18 Nov 2022Beyond Biotech podcast 23: World Antimicrobial Awareness Week, PsychoGenics This week, we have three interviews on the theme of antimicrobial resistance (AMR), to mark World Antimicrobial Awareness Week. We spoke with Holger Zimmermann, CEO of anti-infectives company AiCuris; Neil Clark, CEO of Destiny Pharma, and Fredrik Almqvist, co-founder of QureTech Bio. We also have an interview with the chief scientific officer at PsychoGenics, Mark Varney. […] November 18, 2022 Share WhatsApp Twitter Linkedin Email
News and Trends 17 Nov 2022 New EU project looks to unlock the potential of genomics The European Genomic Data Infrastructure (GDI) project kicked off today in Brussels, Belgium. The new €40 million ($41.4 million) GDI project, coordinated by ELIXIR, is jointly funded by the European Commission under the Digital Europe Programme and through co-funding from participating Member States. In the area of health, the Digital Europe Programme aims to support […] November 17, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 17 Nov 2022 Astellas meets primary endpoint in gastric cancer study Astellas Pharma Inc. has announced positive topline results from its phase 3 SPOTLIGHT clinical trial evaluating the efficacy and safety of zolbetuximab in combination with mFOLFOX6 (a combination regimen that includes oxaliplatin, leucovorin and fluorouracil). Zolbetuximab is an investigational first-in-class monoclonal antibody targeting Claudin 18.2 (CLDN18.2), for the first-line treatment of patients with CLDN18.2-positive, HER2-negative, […] November 17, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 17 Nov 2022 VISEN growth hormone deficiency trial results announced VISEN Pharmaceuticals has published detailed clinical data from its pivotal phase 3 study of lonapegsomatropin, a long-acting prodrug of unmodified somatropin being investigated as a once-weekly injection in children with growth hormone deficiency (GHD) in China. The data showed that lonapegsomatropin demonstrated an annualized height velocity (AHV) of 10.66 cm/year compared to 9.75 cm/year for […] November 17, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 17 Nov 2022 FundaMental Pharma launches with €10M to advance first-in-class neuroprotectant FundaMental Pharma GmbH, a preclinical neuroscience company spun out of Heidelberg University in Germany, has launched with €10 million ($10.4 million) in seed financing. The funding was led by BioGeneration Ventures (BGV) and Thuja Capital, with participation from other investors, including coparion and High-Tech Gründerfonds (HTGF). Built on the research of Hilmar Bading and Jing […] November 17, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 17 Nov 2022 New mitochondria study could pave way for disease treatments Mitochondria, the ‘powerhouses of the cell,’ are important cellular structures that are vital for their role of generating energy. They constantly fuse together and split apart. They contain a small amount of genetic information, mitochondrial DNA (mtDNA). The mtDNA, organized into dot-like structures called nucleoids, also moves around inside the mitochondria. The method of distribution […] November 17, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 16 Nov 2022 Enzymes could be key to understanding ‘origin of DNA errors’ Enzymes, critical to controlling how cells replicate in the human body, could be the very ingredient that encourages DNA to spontaneously mutate – causing potentially permanent genetic errors, according to new research from the University of Surrey in the U.K. Using quantum chemical calculations, researchers from Surrey’s Quantum Biology Doctoral Training Centre have found that […] November 16, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 16 Nov 2022 Growth in UK cell and gene therapy sector continues The Cell and Gene Therapy Catapult (CGT Catapult) has published its ninth annual U.K. cell and gene therapy Good Manufacturing Practice (GMP) manufacturing report, showing continued growth in the advanced therapy medicinal products (ATMP) UK manufacturing sector. This growth is across industry and academia, showing how the sector is responding to the operationalization and skills […] November 16, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 16 Nov 2022 Kadans Science Partner to develop new London life sciences innovation facility Kadans Science Partner and Canary Wharf Group (CWG) are developing a new innovation facility in London, U.K., to provide access to fully-fitted laboratories and space for developing life science companies. Kadans Science Partner is converting levels four and five, totalling 38,000 sq ft, at the BREEAM Outstanding 20 Water Street, into flexible, fully serviced CL2 […] November 16, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 16 Nov 2022 Immutep announces efti clinical results for non-small cell lung cancer Immutep Limited has revealed what it says are compelling new clinical data from its TACTI-002 all-comer PD-L1 phase II trial evaluating Immutep’s lead product candidate, eftilagimod alpha in combination with MSD’s (Merck and Co., Inc., Rahway, N.J., USA) anti-PD-1 therapy KEYTRUDA (pembrolizumab) in 114 patients with non-small cell lung cancer (NSCLC). The new data was […] November 16, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 16 Nov 2022 Poolbeg-led consortium awarded €2.3m to develop oral vaccine platform EncOVac, a consortium led by Poolbeg Pharma, has been awarded €2.3m ($2.4 million) in non-dilutive grant funding to progress its Oral Vaccine Platform under the Irish Government’s Disruptive Technologies Innovation Fund (DTIF). Taking place over three years, the collaboration between Poolbeg Pharma, University College Dublin, Trinity College Dublin and AnaBio Technologies will result in the […] November 16, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 15 Nov 2022 Jnana Therapeutics raises $107M for PKU program and announces new Roche partnership Jnana Therapeutics has entered into a second collaboration and license agreement with Roche for the discovery of small molecule drugs for the treatment of cancer, immune-mediated and neurological diseases. The collaboration covers multiple targets from a diverse range of target classes to address diseases with high unmet need. The company also announced the close of […] November 15, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email